摘要
目的探讨硼替佐米治疗肾功能不全多发性骨髓瘤患者的临床疗效及对血肌酐、尿素氮和24小时尿蛋白量的影响。方法选取2014年10月1日-2020年1月31日某院收治的肾功能不全多发性骨髓瘤患者80例,根据随机数表法分为研究组和对照组,对照组患者给予地塞米松+沙利度胺化疗治疗,研究组使用硼替佐米进行联合治疗,比较2组患者客观缓解率和疾病控制率,并对2组治疗前后实验室检查指标、肾功能指标、免疫功能水平进行比较,观察治疗过程中不良反应发生情况。结果研究组客观缓解率75.00%明显高于对照组47.50%,差异有统计学意义,χ^(2)=6.373,P=0.012;研究组疾病控制率为90.00%,高于对照组的72.50%,差异有统计学意义,χ^(2)=4.021,P=0.045。治疗前2组患者实验室检查指标比较,差异无统计学意义,P>0.05;治疗后研究组血红蛋白、白蛋白高于对照组,球蛋白、红细胞沉降率低于对照组,差异有统计学意义,P<0.05。治疗前2组患者肾功能指标差异无统计学意义,P>0.05;治疗后研究组血肌酐、尿素氮和24小时尿蛋白量均低于对照组,差异有统计学意义,P<0.05。治疗前,2组患者免疫功能水平差异无统计学意义,P>0.05,治疗后研究组CD4+和CD4+/CD8+高于对照组,CD8+低于对照组,差异有统计学意义,P<0.05。研究组患者不良反应发生率为7.50%,低于对照组30.00%,χ^(2)=6.646,P=0.001。结论硼替佐米治疗肾功能不全多发性骨髓瘤患者的临床疗效显著,可改善患者肾功能,提高患者免疫功能,且不良反应较少,安全性较高,值得临床进一步推广。
Objective To investigate the clinical efficacy of bortezomib in the treatment of multiple myeloma with renal insufficiency and its influence on Scr,BUN and urinary protein content at 24 h.Methods Selected October 1,2014-January 31,2020 of the 80 cases of renal dysfunction in patients with multiple myeloma,according to the stochastic indicator method is divided into boron for m group and the control group,control group patients were given dexamethasone+gilad amine chemotherapy,boron for m group for the use of boron with michele for joint treatment,compared two groups of patients with objective response rate and disease control,and the two groups before and after treatment of laboratory examination,renal function,immune function level comparison,observe adverse reactions in two groups of treatment process.Results The objective remission rate of bortezomib group(75.00%)was significantly higher than that of the control group(47.50%)(χ^(2)=6.373,P=0.012).The disease control rate of bortezomib group(90.00%)was significantly higher than that of the control group(72.50%)(χ^(2)=4.021,P=0.045).There was no significant difference in laboratory test index between the two groups before treatment(P>0.05).After treatment,the hemoglobin and albumin of bortezomib group were higher than those of the control group,while the globulin and ESR of bortezomib group were lower than those of the control group,with statistically significant differences(P<0.05).There was no significant difference in renal function between the two groups before treatment(P>0.05).After treatment,the amount of Scr,BUN and urinary protein in bortezomib group was lower than that in the control group at 24 h(P<0.05).After treatment,CD4+and CD4+/CD8+in bortezomib group were higher than those in the control group,while CD8+was lower than those in the control group(P<0.05).The incidence of adverse reactions in bortezomib group(7.50%)was significantly lower than that in the control group(30.00%)(χ^(2)=6.646,P=0.001).Conclusion Bortezomib has significant clinical e
作者
乌云
严怀秀
樊迪
贾波
Wu Yun;Yan Huaixiu;Fan Di;Jia Bo(The Third Hospital of Baotou Steel in Inner Mongolia,Baotou 014010,Inner Mongolia Autonomous region,China;不详)
出处
《中国病案》
2021年第12期109-113,共5页
Chinese Medical Record
